{"schema_version":"secwatch.filing_event.v1","accession":"0000010795-23-000026","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.798751+00:00","generated_at":"2026-06-20T01:48:16.231188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BD reports Q1 FY2023 revenue $4.6B (-2.8% as reported); adj. EPS $2.98; raises guidance","bullets":["Revenue of $4,586M decreased 2.8% as reported, increased 1.7% currency-neutral versus Q1 FY2022.","Base business (ex-COVID diagnostics) revenue grew 0.4% as reported, 5.2% currency-neutral.","GAAP diluted EPS from continuing operations $1.70; adjusted diluted EPS $2.98, down 6.0% YoY.","Company raises full-year fiscal 2023 revenue and adjusted EPS guidance.","Results exclude spun-off Diabetes Care business (Embecta) accounted as discontinued operations."],"urls":{"canonical":"https://secwatch.observer/filing/0000010795-23-000026","json":"https://secwatch.observer/filing/0000010795-23-000026.json","markdown":"https://secwatch.observer/filing/0000010795-23-000026.md","text":"https://secwatch.observer/filing/0000010795-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000001079523000026/0000010795-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000001079523000026/bdx-20230202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:48:16.231188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53eebc1bf06303d409c3e3f23d745d2bee8cd639","claim":"BECTON DICKINSON & CO reported the first quarter of fiscal 2023 ended December 31, 2022 results: revenue $4.6 billion, EPS $1.70. Guidance raised.","evidence_excerpt":"BD Reports First Quarter Fiscal 2023 Financial Results Execution of BD 2025 Strategy Delivering Consistent and Durable Performance • Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis • Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral • GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively • Company raises full-year revenue and adjusted EPS guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10795/000001079523000026/0000010795-23-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of fiscal 2023 ended December 31, 2022"},{"label":"Revenue","value":"$4.6 billion"},{"label":"EPS","value":"$1.70"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}